Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD

Stopped Due to enrollment challenges resulting in changing treatment patterns, the study has been terminated. No patients remain on study.

Conditions

• Squamous Cell Carcinoma of the Head and Neck

Interventions

• BIOLOGICAL: Imprime PGG
• DRUG: Pembrolizumab

Sponsor

HiberCell, Inc.

Collaborators

• [object Object]